Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cornus officinalis extract is a botanical extract derived from the fruit of the *Cornus officinalis* plant, commonly known as dogwood or Shanzhuyu in traditional Chinese medicine. It contains a variety of bioactive compounds, including iridoid glycosides (such as morroniside and loganin), polysaccharides, and flavonoids. The extract is being investigated for its antioxidant, anti-inflammatory, and cytoprotective properties. Recent research indicates it may stimulate the Keap1/Nrf2 antioxidant pathway and reduce the secretion of pro-inflammatory chemokines (e.g., CXCL1, CXCL10, CCL2), suggesting potential therapeutic utility in delaying the onset of Type 1 diabetes and managing Type 2 diabetes. It has also shown promise in providing hepatic, renal, and neuroprotection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cornus officinalis extract.